

**FIG S1.** Loss of Set1 complex members results in altered azole efficacy. (A) Five-fold serial dilution spot assays of the indicated *S. cerevisiae* strains were grown on SC plates with or without 8 µg/mL fluconazole. (B) MIC assay of the indicated strains performed in SC media at 35°C and results recorded after 24 h of incubation. (C) Expression of SET1 was determined in the indicated mutants treated with and without 64 µg/mL fluconazole for 3 h by qRT-PCR analysis. Gene expression analysis was set relative to the untreated wild-type and expression was normalized to *RDN18* mRNA levels. Data were analyzed from 4 biological replicates with three technical replicates each. (D) Whole cell extracts isolated from the indicated strains were immunoblotted using trimethyl-specific and anti-M2-Flag mouse antibodies. Histone H3 was used as a loading control. (E) Five-fold serial dilution spot assays of the indicated 3xFLAG-*SET1* strains were grown on SC plates with or without 32 µg/mL fluconazole. Statistics were performed using Graphpad Prism student t-test version 9.2.0. \*\*\*\*p<0.0001. Error bars represent SD.



**Fig S2.** Transcript levels of drug transporters in a set1 $\Delta$  strain compared to wild type. (A-C) Expression of the indicated genes were determined in the indicated mutants treated with and without 64 µg/mL fluconazole for 3 h by qRT-PCR analysis. Gene expression analysis was set relative to the untreated wild-type and expression was normalized to *RDN18* mRNA levels. Data were analyzed from  $\geq$  3 biological replicates with three technical replicates each. Statistics were performed using Graphpad Prism student t-test version 9.2.0. \*\**p*<0.01. Error bars represent SD. (D-E) Relative fluorescent units of Nile red in wild-type *C. glabrata* and *S. cerevisiae* with and without 64µg/mL fluconazole. (F) Five-fold dilution spot assay of indicated *S. cerevisiae* strains with and without 8 µg/mL fluconazole on minimal media.



**Fig S3.** *Histone H3K4 trimethylation is enriched on ERG gene chromatin and Set1-mediated histone H3K4 methyltransferase activity is required for azole induction of ERG genes in saturated cells.* (A, B) Expression of genes was determined in the indicated strains treated with and without 64 µg/mL fluconazole in a saturated culture for 3 h by qRT-PCR analysis. Gene expression analysis was set relative to the untreated wild-type expression was normalized to *RDN18* mRNA levels. Data were analyzed from  $\geq$  3 biological replicates with three technical replicates each. (C, D) ChIP analysis of histone H3K4 tri-methylation levels at the promoter, 5', and 3' regions of *ERG11* and *ERG3* in a wild-type *C. glabrata* strain with and without 64 µg/mL fluconazole treatment in saturated cell cultures. ChIP analysis was set relative to a *set1Δ* strain and normalized to histone H3 and DNA input levels. Data were analyzed from 3 biological replicates with three technical replicates each. Statistics were performed using Graphpad Prism student t-test version 9.2.0. \*\*\*\*p<0.0001 and \*\*p<0.01. Error bars represent SD.



**Fig S4.** Genes encoding enzymes of the late ergosterol pathway are down in a set1 $\Delta$  strain upon azole treatment in C. glabrata. (A) Volcano plot showing the significance [ $-log_2$  (FDR), yaxis] vs. the fold change (x-axis) of the DEGs identified in the set1 $\Delta$  azole treated samples relative to WT azole treated samples. Genes with significant differential expression (FDR < 0.05) are highlighted in red or blue for up- and downregulated genes, respectively. Downregulated *ERG* genes are labelled in the plot which include 12 of the *ERG* genes in the late pathway and two *ERG* genes in the early pathway. Black highlighted genes are considered nonsignificant. (B) Depiction of the late ergosterol pathway in *C. glabrata*. Azoles inhibit lanosterol 14- $\alpha$ -demethylase, the enzyme encoded by *ERG11*. *NCP1\** and *ERG28\** interact with ergosterol synthesizing enzymes. *ERG29\** is a protein of unknown function involved in ergosterol biosynthesis. Loss of *SET1* results in lower transcript levels of 12 of the 12 genes in the late ergosterol biosynthesis pathway compared to a wild-type strain upon azole treatment. Genes with decreased transcript levels due the loss of *SET1* are surrounded by a solid square.

4



**Fig. S5** *HPLC analysis of total cellular ergosterol.* (A-E) Representative chromatograms of ergosterol extracted from CgWT and *Cgset1* $\Delta$  cells with and without 64 µg/mL fluconazole treatment compared with purified ergosterol (MilliporeSigma). Purified and extracted ergosterol had a retention time of ~1.2 min. Purified cholesterol (MilliporeSigma) was added to the extract yeast as an internal control (data not shown). Standard curves were generated for ergosterol and cholesterol to determine the ergosterol:cholesterol ratio (F) Bar graph and mean ergosterol:cholesterol ratio of the indicated *C. glabrata* strains treated with and without 64 µg/mL fluconazole. (G) Table of values us to generate Figure S5F and Figure 7. Data was obtained from 6 biological replicates.

## Supplemental Tables

Table S1.	Yeast Strains		
Strains	Genotype	Reference	Strain Name
S. cerevisiae BY4741	MATα his3∆ leu2∆0 LYS2 met15∆0 ura3∆0	Open Biosystems	ScWT
Scswd1∆	MATα his3∆ leu2∆0 LYS2 met15∆0 ura3∆0 swd1∆::KanMX	Open Biosystems	Scswd1∆
Scspp1∆	MATα his3∆ leu2∆0 LYS2 met15∆0 ura3∆0 spp1∆::KanMX	Open Biosystems	Scspp1∆
Scbre2∆	MATα his3∆ leu2∆0 LYS2 met15∆0 ura3∆0 bre2∆::KanMX	Open Biosystems	Scbre2A
SDBY1420	MATa his3Δ leu2Δ0 LYS2 met15Δ0 ura3Δ0 set1Δ::HphMX	Zhang et al. Yeast	Scset1A
SDBY1600	MATα his3∆ leu2∆0 LYS2 met15∆0 ura3∆0 HHT1::K4R	This study	ScH3K4R1
SDBY1601	MATα his3∆ leu2∆0 LYS2 met15∆0ura3∆0 HHT1::K4R HHT2 <sup></sup> K4R		
Scpdr5∆	MATα his3Δ leu2Δ0 LYS2 met15Δ0	This study	ScH3K4R2 Scpdr5∆
	ura3∆0 pdr5∆::KanMX	Open Biosystems	
ATCC 2001	C. glabrata wild type strain		
CgVVI	· · · · · · · · · · · · · · · · · · ·	www.atcc.org	CgWT
SDBY1602	set1A::HphMX	This study	Cgset1∆
SDBY1603	swd1∆::HphMX	This study	Cgswd1∆
SDBY1604	spp1∆::HphMX	This study	Cgspp1∆
SDBY1605	bre2∆::HphMX	This study	Cgbre2∆
SDBY1606	pdr1∆::NatMX	This study	Cgpdr1∆
ATCC 200989	his3∆ trp1∆ ura3∆		0.11/7
	bio20 tro10 uro20 oot10 UphMX	www.atcc.org	CgWI
30011007		This study	Cgset1∆
SM1	susceptible	Magill et al. JCM	SM1
SM3	C. glabrata isolate fluconazole resistant	Magill et al. JCM Caudle et al. Euk.	SM3
SM1 <i>pdr1∆</i>	<i>pdr1::</i> FRT	Cell	SM1 <i>pdr1∆</i>
SDBY1608	set1∆::HphMX	This study	SM1 <i>set1∆</i>
SDBY1609	set1∆::HphMX	This study	SM3 <i>set1∆</i>
SDBY1610	set1∆::HphMX pdr1::FRT	This study	SM1 <i>set1∆pdr1∆</i>

Table S2.	Plasmids			
Plasmid	Inserted Gene	Promoter	Vector	Source
pGRB2.0	None		pGRB2.0	Zordan et al.
pGRB2.0	SET1	SET1	pGRB2.0	Zordan et al.
pGRB2.0	SET1/H1048K	SET1	pGRB2.0	Zordan et al.
pGRB2.0	3XFLAGSET1	SET1	pGRB2.0	Zordan et al.
pGRB2.0	3XFLAGSET1/H1048K	SET1	pGRB2.0	Zordan et al.

Table S3.	Primers for qRT-PCR
Primer Name	Sequence
CgRDN18-001F	ACGGAGCCAGCGAGTCTAAC
CgRDN18-002R	CGACGGAGTTTCACAAGATTACC
CgERG3-001F	TGGGAGCACCACGGTCTAAG
CgERG3-002R	CAGTCGGTGAAGAAGATGAAAGTG
CgERG11-001F	GGGTCCAAAGGGTCACGAA
CgERG11-002R	GCAGCTTCAGCGGAAACATC
CgCDR1-001F	GTCTATGGAAGGTGCCGTCAA
CgCDR1-002R	TGAACCAGGTCTACCTAGCACAAC
CgPDR1-001F	TCGGCGAGGGTAAATTCAAC
CgPDR1-002R	CAACTGCGTTTGATTCCTTAAGC
CgSET1-001F	CCAACCAAAGCCGATACTCATC
CgSET1-002R	GCGTTGACTACCGCGAGATT
CgYOR1-001F	GTACAGAGTGTGCCGGAACAAG
CgYOR1-002R	TGCGTCACCTTCTCTATGTCGTT
CgPDH1-001F	GAGTCCGCCGATGTGTCAT
CgPDH1-002R	CAGCTTCACGGGCAGGTT
CgSNQ2-001F	CCCCGGCGGATAAACTAAC
CgSNQ2-002R	CTGGCTCGCAGTGTCTCTTG
ScRDN18-001F	TGGTGCATGGCCGTTCTTA
ScRDN18-002R	GGTCTCGTTCGTTATCGCAATT
ScERG11-001F	CTACCTACAAGGATGGTGTGAAG
ScERG11-002R	CAGAAGTGGCAGCAGAAGTAT
ScPDR5-001F	ATTCACCAACCCTCTGCTATTT
ScPDR5-002R	TTACAACCTTCGCCCAAGTC
ScPDR1-001F	CGGGCACTTCATGCTTACTA
ScPDR1-002R	CTCCGGTAGTGAGTTGTTTCTC

Table S4.	Probe sets for ChIP Analysis
Probe Name	Sequence 5'-3'
ERG11 Promoter	/56-FAM/CCTTGTTCC/ZEN/AACTACAATCGAGTGAGCT/3IABkFQ/
	CGAATACGAGGCCATTTGTAAAC
	CTGTGCTCCCATCTCACTATAAC
ERG11 5'	/56-FAM/TCGTACTTC/ZEN/CAAGCTCTGCCATTGG/3IABkFQ/
	GAGTACGTGAAGCTTGGTCTT

	CCGGTGTTTCCTGTCTAGTT
	AGAAACCGCCGCTTACAT
ERG3 3'	/56-FAM/CCAAGAGGT/ZEN/GGAAGGTGACGACAC/3IABkFQ/
	ATGCAGCAGCGTAGAGTTAG
	CGACGATGTGTATGCCAAGA
ERG3 5'	/56-FAM/TCGACGACT/ZEN/CGTTGGTCAATGCTT/3IABkFQ/
	TCTTCTTCCAGGCCTCATCT
	GAGACTATACGAGTGTGCTCTTTG
ERG3 Promoter	/56-FAM/AGCGAGAGC/ZEN/TGCTAGAGCTGAGAA/3IABkFQ/
	AGCAGCAAAGCCCTCTAAA
	ACGGGATATACGCTGATTCATT
ERG11 3'	/56-FAM/CGGCATGAC/ZEN/TTAAGCTGGTTGTTTCG/3IABkFQ/
	TGGCAAGGCGACCATAATAG

Table S5. qRT-PCR Values										
Figure 4A: qRT-PCR										
Gene	Strain	Condition	Mean RQ	St Dev		Ν	P-Value			
ScPDR5	ScWT	Untreated	1.027		0.28	4	n.s.			
ScPDR5	ScWT	(+) fluconazole	1.16		0.30	4	n.s.			
ScPDR5	Scset1∆	Untreated	0.45		0.08	4	<0.01			
ScPDR5	Scset1∆	(+) fluconazole	0.515		0.17	4	<0.01			
Figure 4B: qRT-PCR										
Gene	Strain	Condition	Mean RQ	St Dev		Ν	P-Value			
ScPDR1	ScWT	Untreated	1.13		0.58	3	n.s.			
ScPDR1	ScWT	(+) fluconazole	1.39		0.1	3	n.s.			
ScPDR1	Scset1∆	Untreated	1.17		0.57	3	n.s.			
ScPDR1	Scset1∆	(+) fluconazole	1.73		0.37	3	n.s.			
Figure 4D: qRT-PCR										
Gene	Strain	Condition	Mean RQ	St Dev		Ν	P-Value			
CgCDR1	<i>Cg</i> WT	Untreated	1		0.75	7	n.s.			
CgCDR1	<i>Cg</i> WT	(+) fluconazole	4.51		1.07	7	n.s.			
CgCDR1	Cgset1∆	Untreated	1.1		0.97	7	n.s.			
CgCDR1	Cgset1∆	(+) fluconazole	4.04		0.61	7	n.s.			
		Figure 4E: qR	T-PCR							
Gene	Strain	Condition	Mean RQ	St Dev			P-Value			
CgPDR1	<i>Cg</i> WT	Untreated	1		0.26	3	n.s.			
CgPDR1	<i>Cg</i> WT	(+) fluconazole	2.29		0.20	3	n.s.			
CgPDR1	Cgset1∆	Untreated	1.02		0.35	3	n.s.			
CgPDR1	Cgset1∆	(+) fluconazole	2.29		0.25	3	n.s.			
		Figure 5E: qR	T-PCR							
Gene	Strain	Condition	Mean RQ	St Dev			P-Value			
CgERG11	<i>Cg</i> WT	Untreated	1		0.32	3	n.s.			
CgERG11	<i>Cg</i> WT	(+) fluconazole	10.29		0.23	3	n.s.			
CgERG11	Cgset1∆	Untreated	1.32		0.65	3	n.s.			
CgERG11	Cgset1∆	(+) fluconazole	3.83		0.26	3	<0.0001			
	Figure 5F: gRT-PCR									

Gene	Strain	Condition	Mean RQ	St Dev		P-Value	
CgERG3	<i>Cg</i> WT	Untreated	1	0.1	3	n.s.	
CgERG3	<i>Cg</i> WT	(+) fluconazole	3.63	0.69	3	n.s.	
CgERG3	Cgset1∆	Untreated	1.14	0.05	3	n.s.	
CgERG3	Cgset1∆	(+) fluconazole	0.9	0.18	3	<0.0001	
		Figure 5G: qR	T-PCR				
Gene	Strain	Condition	Mean RQ	St Dev		P-Value	
ScERG11	ScWT	Untreated	1.022	0.12	4	n.s.	
ScERG11	ScWT	(+) fluconazole	3.649	0.85	4	n.s.	
ScERG11	Scset1∆	Untreated	0.696	0.11	4	<0.001	
ScERG11	Scset1∆	(+) fluconazole	3.151	1.17	4	n.s.	
		Figure 6A: ChIP	qRT-PCR				
Gene	Strain	Condition	Mean RQ	St Dev		P-Value	
CgERG11	CgWT promoter	Untreated	11.24	5.57	3	n.s.	
CgERG11	CgWT promoter	(+) fluconazole	22.138	12.01	3	n.s.	
CgERG11	CgWT 5'	Untreated	62.531	1.45	3	n.s.	
CgERG11	CgWT 5'	(+) fluconazole	133.274	20.39	3	<0.001	
CgERG11	CgWT 3'	Untreated	11.412	3.19	3	n.s.	
CgERG11	CgWT 3'	(+) fluconazole	26.019	7.85	3	<0.05	
	Figure 6B: ChIP qRT-PCR						
Gene	Strain	Condition	Mean RQ	St Dev		P-Value	
CgERG3	<i>Cg</i> WT	Untreated	35.768	18.27	3	n.s.	
CgERG3	<i>Cg</i> WT	(+) fluconazole	57.996	35.32	3	n.s.	
CgERG3	<i>Cg</i> WT 5'	Untreated	145.877	42.57	3	n.s.	
CgERG3	<i>Cg</i> WT 5'	(+) fluconazole	281.392	69.12	3	<0.05	
CgERG3	CgWT 3'	Untreated	50.262	13.74	3	n.s.	
CgERG3	CgWT 3'	(+) fluconazole	133.95	59.06	3	n.s.	
		Figure 6C: qR	T-PCR				
Gene	Strain	Condition	Mean RQ	St Dev		P-Value	
CgERG11	CgWT+V	Untreated	0.951	0.38	4	n.s.	
CgERG11	<i>Cg</i> WT+V	(+) fluconazole	6.791	1.99	4	n.s.	
CgERG11	<i>Cgset1</i> ∆+V	Untreated	1.342	0.55	4	n.s.	
CgERG11	<i>Cgset1</i> ∆+V	(+) fluconazole	2.603	1.04	4	<0.01	
CgERG11	Cgset1∆/SET1	Untreated	1.227	0.63	4	n.s.	
CgERG11	Cgset1∆/SET1	(+) fluconazole	6.438	2.78	4	n.s.	
CgERG11	Cgset1∆/H1048K	Untreated	1.346	0.43	4	n.s.	
CgERG11	Cgset1∆/H1048K	(+) fluconazole	3.370	0.87	4	<0.05	
		Figure 6D: qR	T-PCR	<u>.</u>			
Gana	Strain	Condition	Maan BO	Standard		D Value	
Gene CaEBC2		Untrooted			٨	r-value	
	CgVVT+V		1.200	1.14	4	n.s.	
CAERCO	$C_{q_{1}}$			Z. 14	4 ∕	n.ə.	
CAEPC2	$C_{\alpha} = t_1 \wedge t_1 \wedge t_1 \wedge t_2 \wedge t_1 \wedge t_2 \wedge t_1 \wedge t_2 \wedge t_$		U.014	0.30	4 1	n.s.	
CaEPC2	Caset1A/SET1		1.012	0.43	4 1	n.s.	
			1.034	0.04	4 1	11.S. ∠0.001	
CAEPCO			7.518	4.23	4 1	<b>\U.UU</b> I	
CYERGS	Ugset 12/H1048K	Uniteated	0.888	0.21	4	n.s.	

CgERG3	Cgset1∆/H1048K	(+) fluconazole	2.357	0.54	4	< 0.05		
Figure 8E: qRT-PCR								
Gene	Strain	Condition	Mean RQ St	Dev		P-Value		
CgERG11	SM1 <i>Cg</i> WT	Untreated	1.15	0.72	3	n.s.		
CgERG11	SM1 <i>Cg</i> WT	(+) fluconazole	19.69	6.49	3	n.s.		
CgERG11	SM1 <i>Cgset1</i> ∆	Untreated	1.04	0.89	3	n.s.		
CgERG11	SM1 <i>Cgset1</i> ∆	(+) fluconazole	6.3	3.80	3	<0.05		
		Figure 8F: qR	T-PCR					
Gene	Strain	Condition	Mean RQ	St Dev		P-Value		
CgERG11	SM3 CgWT	Untreated	1.51	1.66	5	n.s.		
CgERG11	SM3 CgWT	(+) fluconazole	6.15	1.63	5	n.s.		
CgERG11	SM3 Cgset1∆	Untreated	1.54	0.76	5	n.s.		
CgERG11	SM3 Cgset1∆	(+) fluconazole	2.87	0.42	5	<0.01		